Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in:

Open Access 01-12-2023 | Metastasis | Review

Flavonoids target different molecules of autophagic and metastatic pathways in cancer cells

Authors: Aysooda Hosseinzadeh, Faezeh Poursoleiman, Akram Naghdipour Biregani, Ahmad Esmailzadeh

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Despite the success of cancer therapy, it has encountered a major obstacle due to the complicated nature of cancer, namely resistance. The recurrence and metastasis of cancer occur when anti-cancer therapeutic agents fail to eradicate all cancer cells. Cancer therapy aims to find the best agent that targets all cancer cells, including those sensitive or resistant to treatment. Flavonoids, natural products from our diet, show anti-cancer effects in different studies. They can inhibit metastasis and the recurrence of cancers. This review discusses metastasis, autophagy, anoikis in cancer cells, and their dynamic relationship. We present evidence that flavonoids can block metastasis and induce cell death in cancer cells. Our research suggests that flavonoids can serve as potential therapeutic agents in cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Kumar S, Pandey AK. Chemistry and Biological Activities of Flavonoids: An Overview. Sci World J. 2013;2013.
2.
Wang T-y, Li Q, Bi K-s. Bioactive flavonoids in medicinal plants: structure, activity and biological fate. Asian J Pharm Sci. 2018;13(1):12–23.PubMedCrossRef
3.
4.
5.
Singh M, Yelle N, Venugopal C, Singh SK. EMT: mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80–94.PubMedCrossRef
6.
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. editors. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol; 2015: Elsevier.
7.
Babaei G, Aziz SG-G, Jaghi NZZ. EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.PubMedCrossRef
8.
Huang F, Wang B-R, Wang Y-G. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol. 2018;24(41):4643.PubMedPubMedCentralCrossRef
9.
10.
Farhan M, Silva M, Li S, Yan F, Fang J, Peng T, et al. The role of FOXOs and autophagy in cancer and metastasis—implications in therapeutic development. Med Res Rev. 2020;40(6):2089–113.PubMedPubMedCentralCrossRef
11.
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42.PubMedCrossRef
12.
13.
14.
15.
Ke B, Tian M, Li J, Liu B, He G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med Res Rev. 2016;36(6):983–1035.PubMedCrossRef
16.
17.
Zhu Y, Zhao L, Liu L, Gao P, Tian W, Wang X, et al. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell. 2010;1(5):468–77.PubMedPubMedCentralCrossRef
18.
Zhu X, Huang L, Gong J, Shi C, Wang Z, Ye B, et al. NF-κB pathway link with ER stress-induced autophagy and apoptosis in cervical tumor cells. Cell Death Discov. 2017;3(1):1–8.CrossRef
19.
Wirawan E, Vande Walle L, Kersse K, Cornelis S, Claerhout S, Vanoverberghe I, et al. Caspase-mediated cleavage of Beclin-1 inactivates beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis. 2010;1(1):e18–e.PubMedPubMedCentralCrossRef
20.
Puissant A, Auberger P. AMPK-and p62/SQSTM1-dependent autophagy mediate resveratrol-induced cell death in chronic myelogenous leukemia. Autophagy. 2010;6(5):655–7.PubMedCrossRef
21.
Chatterjee SJ, Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol Ther. 2011;11(2):216–28.PubMedCrossRef
22.
Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol. 2007;72(1):29–39.PubMedCrossRef
23.
Zhang L, Cheng X, Gao Y, Zheng J, Xu Q, Sun Y, et al. Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells. Food Funct. 2015;6(11):3464–72.PubMedCrossRef
24.
Lin C-M, Chen H-H, Lin C-A, Wu H-C, Sheu JJ-C, Chen H-J. Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling. Sci Rep. 2017;7(1):1–17.
25.
Lang F, Qin Z, Li F, Zhang H, Fang Z, Hao E. Apoptotic cell death induced by resveratrol is partially mediated by the autophagy pathway in human ovarian cancer cells. PLoS ONE. 2015;10(6):e0129196.PubMedPubMedCentralCrossRef
26.
Suh Y, Afaq F, Khan N, Johnson JJ, Khusro FH, Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis. 2010;31(8):1424–33.PubMedPubMedCentralCrossRef
27.
Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress-and mitochondrial stress-dependent pathways. Cell Death Dis. 2019;10(2):1–15.CrossRef
28.
Zheng N, Zhang P, Huang H, Liu W, Hayashi T, Zang L, et al. ERα down-regulation plays a key role in silibinin-induced autophagy and apoptosis in human breast cancer MCF-7 cells. J Pharmacol Sci. 2015;128(3):97–107.PubMedCrossRef
29.
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P, et al. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci. 2015;16(4):8415–29.PubMedPubMedCentralCrossRef
30.
Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene. 2017;36(12):1619–30.PubMedCrossRef
31.
Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14(1):1–14.CrossRef
32.
Dower CM, Wills CA, Frisch SM, Wang H-G. Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy. 2018;14(7):1110–28.PubMedPubMedCentralCrossRef
33.
Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):1–16.CrossRef
34.
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):1–24.PubMedPubMedCentral
35.
36.
Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci. 2013;110(50):20224–9.PubMedPubMedCentralCrossRef
37.
Ghedalia-Peled NB, Cohen-Erez I, Rapaport H, Vago R. Aggressiveness of 4T1 breast cancer cells hampered by wnt production-2 inhibitor nanoparticles: an in vitro study. Int J Pharm. 2021;596:120208.PubMedCrossRef
38.
Do M, Wu CC, Sonavane PR, Juarez EF, Adams SR, Ross J, et al. A FZD7-specific antibody–drug Conjugate induces ovarian Tumor Regression in Preclinical Models. Mol Cancer Ther. 2022;21(1):113–24.PubMedCrossRef
39.
Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013.
40.
Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chand AL, editors. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin Cancer Biol; 2021: Elsevier.
41.
Liu Y, Liao S, Bennett S, Tang H, Song D, Wood D, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021;54(2):e12974.PubMedCrossRef
42.
Abdin SM, Tolba MF, Zaher DM, Omar HA. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells. Chem Biol Interact. 2021;340:109450.PubMedCrossRef
43.
Tajbakhsh A, Rivandi M, Abedini S, Pasdar A, Sahebkar A. Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): a review. Crit Rev Oncol Hematol. 2019;140:17–27.PubMedCrossRef
44.
Suhail M, Tarique M, Muhammad N, Naz H, Hafeez A, Zughaibi TA, et al. A critical transcription factor NF-κB as a cancer therapeutic target and its inhibitors as cancer treatment options. Curr Med Chem. 2021;28(21):4117–32.PubMedCrossRef
45.
Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem Pharmacol. 2010;79(9):1272–80.PubMedPubMedCentralCrossRef
46.
Murtaza I, Adhami VM, Hafeez BB, Saleem M, Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3‐mediated inhibition of NF‐κB. Int J Cancer. 2009;125(10):2465–73.PubMedPubMedCentralCrossRef
47.
Zhang X-J, Jia S-S. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways. Biomed Pharmacother. 2016;83:1164–74.PubMedCrossRef
48.
Khan N, Asim M, Afaq F, Zaid MA, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008;68(20):8555–63.PubMedPubMedCentralCrossRef
49.
Jeng LB, Kumar Velmurugan B, Chen MC, Hsu HH, Ho TJ, Day CH, et al. Fisetin mediated apoptotic cell death in parental and Oxaliplatin/irinotecan resistant colorectal cancer cells in vitro and in vivo. J Cell Physiol. 2018;233(9):7134–42.PubMedCrossRef
50.
Lin M-T, Lin C-L, Lin T-Y, Cheng C-W, Yang S-F, Lin C-L, et al. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumor Biol. 2016;37(5):6987–96.CrossRef
51.
Casella ML, Parody JP, Ceballos MP, Quiroga AD, Ronco MT, Francés DE, et al. Quercetin prevents liver carcinogenesis by inducing cell cycle arrest, decreasing cell proliferation and enhancing apoptosis. Mol Nutr Food Res. 2014;58(2):289–300.PubMedCrossRef
52.
Pratheeshkumar P, Budhraja A, Son Y-O, Wang X, Zhang Z, Ding S et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE. 2012;7(10).
53.
Rivera AR, Castillo-Pichardo L, Gerena Y, Dharmawardhane S. Anti-breast cancer potential of quercetin via the Akt/AMPK/mammalian target of rapamycin (mTOR) signaling cascade. PLoS ONE. 2016;11(6).
54.
Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer. 2002;98(5):761–9.PubMedCrossRef
55.
Jung M, Bu SY, Tak K-H, Park J-E, Kim E. Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer. Nutr Res Pract. 2013;7(6):439–45.PubMedPubMedCentralCrossRef
56.
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial–mesenchymal transition and stemness. Cell Signal. 2013;25(12):2625–33.PubMedCrossRef
57.
Sancho P, Burgos-Ramos E, Tavera A, Kheir TB, Jagust P, Schoenhals M, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 2015;22(4):590–605.PubMedCrossRef
58.
Seo H-S, Jo JK, Ku JM, Choi H-S, Choi YK, Woo J-K et al. Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Biosci Rep. 2015;35(6).
59.
Liu X, Li L, Lv L, Chen D, Shen L, Xie Z. Apigenin inhibits the proliferation and invasion of osteosarcoma cells by suppressing the Wnt/β-catenin signaling pathway. Oncol Rep. 2015;34(2):1035–41.PubMedCrossRef
60.
Zhao G, Han X, Zheng S, Li Z, Sha Y, Ni J, et al. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells. Oncol Rep. 2016;35(2):1065–74.PubMedCrossRef
61.
Masuelli L, Benvenuto M, Di Stefano E, Mattera R, Fantini M, De Feudis G, et al. Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget. 2017;8(21):34405.PubMedPubMedCentralCrossRef
62.
Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012;16(11):1195–204.PubMedPubMedCentralCrossRef
63.
Wani ZA, Guru SK, Rao AS, Sharma S, Mahajan G, Behl A, et al. A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT-116 cells. Food Chem Toxicol. 2016;87:1–11.PubMedCrossRef
64.
Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, et al. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep. 2017;37(2):895–902.PubMedCrossRef
65.
Yao Y, Rao C, Zheng G, Wang S. Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR–384/pleiotrophin axis. Oncol Rep. 2019;42(1):131–41.PubMedPubMedCentralCrossRef
66.
Frey RS, Singletary KW. Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. J Nutr. 2003;133(1):226–31.PubMedCrossRef
67.
Wang H, Luo Y, Qiao T, Wu Z, Huang Z. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. J Ovarian Res. 2018;11(1):93.PubMedPubMedCentralCrossRef
68.
Liu H, Zeng Z, Wang S, Li T, Mastriani E, Li Q-H, et al. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther. 2017;18(12):990–9.PubMedPubMedCentralCrossRef
69.
Bartmańska A, Tronina T, Popłoński J, Milczarek M, Filip-Psurska B, Wietrzyk J. Highly cancer selective antiproliferative activity of natural prenylated flavonoids. Molecules. 2018;23(11):2922.PubMedPubMedCentralCrossRef
70.
Khan N, Afaq F, Syed DN, Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis. 2008;29(5):1049–56.PubMedPubMedCentralCrossRef
71.
Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. (–)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 2005;11(7):2735–46.PubMedCrossRef
72.
Li S, Yuan S, Zhao Q, Wang B, Wang X, Li K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 2018;100:441–7.PubMedCrossRef
73.
Alataki A, Dowsett M. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer. Endocr Relat Cancer. 2022;1(aop).
74.
Girisa S, Saikia Q, Bordoloi D, Banik K, Monisha J, Daimary UD, et al. Xanthohumol from hop: hope for cancer prevention and treatment. IUBMB Life. 2021;73(8):1016–44.PubMedCrossRef
75.
Vanhoecke BW, Delporte F, Van Braeckel E, Heyerick A, Depypere HT, Nuytinck M, et al. A safety study of oral tangeretin and xanthohumol administration to laboratory mice. In vivo. 2005;19(1):103–7.PubMed
76.
Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, et al. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016;7(43):70794.PubMedPubMedCentralCrossRef
77.
Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, et al. Randomized, Placebo-Controlled Trial of Green Tea catechins for prostate Cancer PreventionGreen Tea catechins and prostate Cancer. Cancer Prev Res. 2015;8(10):879–87.CrossRef
78.
Zhu W, Mei H, Jia L, Zhao H, Li X, Meng X, et al. Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial. Invest New Drugs. 2020;38:1129–36.PubMedCrossRef
79.
Zhao H, Zhu W, Jia L, Sun X, Chen G, Zhao X, et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br J Radiol. 2016;89(1058):20150665.PubMedCrossRef
80.
Trudel D, Labbé DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, et al. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013;131(2):357–61.PubMedCrossRef
81.
Zhao H, Zhu W, Xie P, Li H, Zhang X, Sun X, et al. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer. Radiother Oncol. 2014;110(1):132–6.PubMedCrossRef
82.
Almatroodi SA, Almatroudi A, Khan AA, Alhumaydhi FA, Alsahli MA, Rahmani AH. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules. 2020;25(14):3146.PubMedPubMedCentralCrossRef
83.
Jing-Jing L, Qi-Hua G, Min L, Hua-Ping Y, Li-Ming C, Cheng-Ping H. Role of Ku70 and bax in epigallocatechin-3-gallate–induced apoptosis of A549 cells in vivo. Oncol Lett. 2013;5(1):101–6.CrossRef
84.
Kausar H, Jeyabalan J, Aqil F, Chabba D, Sidana J, Singh IP, et al. Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cells. Cancer Lett. 2012;325(1):54–62.PubMedCrossRef
85.
Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, et al. Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models. Br J Cancer. 2016;114(8):905–16.PubMedPubMedCentralCrossRef
86.
Chien M-H, Lin Y-W, Wen Y-C, Yang Y-C, Hsiao M, Chang J-L, et al. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J Exp Clin Cancer Res. 2019;38(1):1–17.CrossRef
87.
Wei R, Cortez Penso NE, Hackman RM, Wang Y, Mackenzie GG. Epigallocatechin-3-gallate (EGCG) suppresses pancreatic cancer cell growth, invasion, and migration partly through the inhibition of akt pathway and epithelial–mesenchymal transition: enhanced efficacy when combined with gemcitabine. Nutrients. 2019;11(8):1856.PubMedPubMedCentralCrossRef
88.
Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018:1300.
89.
Liskova A, Samec M, Koklesova L, Brockmueller A, Zhai K, Abdellatif B, et al. Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J. 2021;12(2):155–76.PubMedPubMedCentralCrossRef
90.
Tiwari P, Mishra KP. Flavonoids sensitize tumor cells to radiation: molecular mechanisms and relevance to cancer radiotherapy. Int J Radiat Biol. 2020;96(3):360–9.PubMedCrossRef
91.
Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci. 2020;16(7):1121.PubMedPubMedCentralCrossRef
92.
Huang S, Yu M, Shi N, Zhou Y, Li F, Li X, et al. Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. J Cancer. 2020;11(8):2123.PubMedPubMedCentralCrossRef
93.
Medhat AM, Azab KS, Said MM, El Fatih NM, El Bakary NM. Antitumor and radiosensitizing synergistic effects of apigenin and cryptotanshinone against solid Ehrlich carcinoma in female mice. Tumor Biol. 2017;39(10):1010428317728480.CrossRef
94.
Lin C, Yu Y, Zhao H-g, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol. 2012;104(3):395–400.PubMedCrossRef
95.
Navarra M, Femia AP, Romagnoli A, Tortora K, Luceri C, Cirmi S, et al. A flavonoid-rich extract from bergamot juice prevents carcinogenesis in a genetic model of colorectal cancer, the Pirc rat (F344/NTac-Apcam1137). Eur J Nutr. 2020;59(3):885–94.PubMedCrossRef
96.
Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008;8(1):1–10.CrossRef
97.
Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013;119(2):363–70.PubMedCrossRef
98.
Amawi H, Ashby CR Jr, Tiwari AK. Cancer chemoprevention through dietary flavonoids: what’s limiting? Cancer Commun. 2017;36(1):1–13.
99.
100.
Hollman P, Katan M. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol. 1999;37(9–10):937–42.PubMedCrossRef
101.
VISKUPIČOVÁ J, ONDREJOVIČ M. ŠTURDÍK E. Bioavailability and metabolism of flavonoids. J Food Nutr Res. 2008;47(4).
102.
Zhou D, Bai Z, Guo T, Li J, Li Y, Hou Y et al. Dietary flavonoids and human top-ranked diseases: the perspective of in vivo bioactivity and bioavailability. Trends Food Sci Technol. 2022.
103.
Chaurasia S, Patel RR, Vure P, Mishra B. Potential of cationic-polymeric nanoparticles for oral delivery of naringenin: in vitro and in vivo investigations. J Pharm Sci. 2018;107(2):706–16.PubMedCrossRef
104.
Li H, Li M, Fu J, Ao H, Wang W, Wang X. Enhancement of oral bioavailability of quercetin by metabolic inhibitory nanosuspensions compared to conventional nanosuspensions. Drug Deliv. 2021;28(1):1226–36.PubMedPubMedCentralCrossRef
105.
Bhia M, Motallebi M, Abadi B, Zarepour A, Pereira-Silva M, Saremnejad F, et al. Naringenin nano-delivery systems and their therapeutic applications. Pharmaceutics. 2021;13(2):291.PubMedPubMedCentralCrossRef
106.
Zhang Z, Huang Y, Gao F, Gao Z, Bu H, Gu W, et al. A self-assembled nanodelivery system enhances the oral bioavailability of daidzein: in vitro characteristics and in vivo performance. Nanomedicine. 2011;6(8):1365–79.PubMedCrossRef
107.
Shen Q, Li X, Li W, Zhao X. Enhanced intestinal absorption of daidzein by borneol/menthol eutectic mixture and microemulsion. AAPS PharmSciTech. 2011;12(4):1044–9.PubMedPubMedCentralCrossRef
108.
Cao H, Jing X, Wu D, Shi Y. Methylation of genistein and kaempferol improves their affinities for proteins. Int J Food Sci. 2013;64(4):437–43.CrossRef
109.
Walle T. Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Mol Pharm. 2007;4(6):826–32.PubMedCrossRef
110.
111.
Rakha A, Umar N, Rabail R, Butt MS, Kieliszek M, Hassoun A, et al. Anti-inflammatory and anti-allergic potential of dietary flavonoids: a review. Biomed Pharmacother. 2022;156:113945.PubMedCrossRef
112.
Hoensch HP, Oertel R. Emerging role of bioflavonoids in gastroenterology: especially their effects on intestinal neoplasia. World J Gastrointest Oncol. 2011;3(5):71.PubMedPubMedCentralCrossRef
113.
114.
Zhu J, Chen C, Zhang B, Huang Q. The inhibitory effects of flavonoids on α-amylase and α-glucosidase. Crit Rev Food Sci Nutr. 2020;60(4):695–708.PubMedCrossRef
115.
Wang M, Firrman J, Liu L, Yam K. A review on flavonoid apigenin: Dietary intake, ADME, antimicrobial effects, and interactions with human gut microbiota. Biomed Res Int. 2019;2019.
116.
Skibola CF, Smith MT. Potential health impacts of excessive flavonoid intake. Free Radic Biol Med. 2000;29(3–4):375–83.PubMedCrossRef
117.
Eghbaliferiz S, Iranshahi M. Prooxidant activity of polyphenols, flavonoids, anthocyanins and carotenoids: updated review of mechanisms and catalyzing metals. Phytother Res. 2016;30(9):1379–91.PubMedCrossRef
118.
Syed DN, Afaq F, Maddodi N, Johnson JJ, Sarfaraz S, Ahmad A, et al. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol. 2011;131(6):1291–9.PubMedPubMedCentralCrossRef
119.
Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-κB-signaling pathways. Carcinogenesis. 2009;30(2):300–7.PubMedCrossRef
120.
Sung B, Pandey MK, Aggarwal BB. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-κB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IκBα kinase activation. Mol Pharmacol. 2007;71(6):1703–14.PubMedCrossRef
121.
Zhang L, Huang Y, Zhuo W, Zhu Y, Zhu B, Chen Z. Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways. Am J Transl Res. 2016;8(11):4857.PubMedPubMedCentral
122.
Klimaszewska-Wiśniewska A, Hałas-Wiśniewska M, Grzanka A, Grzanka D. Evaluation of anti-metastatic potential of the combination of fisetin with paclitaxel on A549 non-small cell lung cancer cells. Int J Mol Sci. 2018;19(3):661.PubMedPubMedCentralCrossRef
123.
Seo H-S, Ku JM, Choi H-S, Choi YK, Woo J-K, Kim M, et al. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells. Oncol Rep. 2016;36(1):31–42.PubMedPubMedCentralCrossRef
124.
Ranganathan S, Halagowder D, Sivasithambaram ND. Quercetin suppresses twist to induce apoptosis in MCF-7 breast cancer cells. PLoS ONE. 2015;10(10):e0141370.PubMedPubMedCentralCrossRef
125.
Lee Y-K, Park SY, Kim Y-M, Lee WS, Park OJ. AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med. 2009;41(3):201–7.PubMedPubMedCentralCrossRef
126.
Lin C-W, Hou W-C, Shen S-C, Juan S-H, Ko C-H, Wang L-M, et al. Quercetin inhibition of tumor invasion via suppressing PKCδ/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 2008;29(9):1807–15.PubMedCrossRef
127.
Granato M, Rizzello C, Montani MSG, Cuomo L, Vitillo M, Santarelli R, et al. Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. J Nutr Biochem. 2017;41:124–36.PubMedCrossRef
128.
Mojsin M, Vicentic JM, Schwirtlich M, Topalovic V, Stevanovic M. Quercetin reduces pluripotency, migration and adhesion of human teratocarcinoma cell line NT2/D1 by inhibiting Wnt/β-catenin signaling. Food Funct. 2014;5(10):2564–73.PubMedCrossRef
129.
Chang J-H, Lai S-L, Chen W-S, Hung W-Y, Chow J-M, Hsiao M, et al. Quercetin suppresses the metastatic ability of lung cancer through inhibiting snail-dependent akt activation and snail-independent ADAM9 expression pathways. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1746–58.PubMedCrossRef
130.
Priyadarsini RV, Murugan RS, Maitreyi S, Ramalingam K, Karunagaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur J Pharmacol. 2010;649(1–3):84–91.CrossRef
131.
Park CH, Chang JY, Hahm ER, Park S, Kim H-K, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 2005;328(1):227–34.PubMedCrossRef
132.
Shukla S, Gupta S. Molecular mechanisms for apigenin-induced cell‐cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog. 2004;39(2):114–26.PubMedCrossRef
133.
Seo HS, Ku JM, Choi HS, Woo JK, Jang BH, Go H, et al. Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells. Mol Med Rep. 2015;12(2):2977–84.PubMedCrossRef
134.
Chang J-H, Cheng C-W, Yang Y-C, Chen W-S, Hung W-Y, Chow J-M, et al. Downregulating CD26/DPPIV by apigenin modulates the interplay between akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses. J Exp Clin Cancer Res. 2018;37(1):1–16.CrossRef
135.
Zhou Z, Tang M, Liu Y, Zhang Z, Lu R, Lu J. Apigenin inhibits cell proliferation, migration, and invasion by targeting akt in the A549 human lung cancer cell line. Anticancer Drugs. 2017;28(4):446–56.PubMedCrossRef
136.
Xu M, Wang S, Song Y, Yao J, Huang K, Zhu X. Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway. Oncol lett. 2016;11(5):3075–80.PubMedPubMedCentralCrossRef
137.
Tsai P-H, Cheng C-H, Lin C-Y, Huang Y-T, Lee L-T, Kandaswami CC, et al. Dietary flavonoids luteolin and quercetin suppressed cancer stem cell properties and metastatic potential of isolated prostate cancer cells. Anticancer Res. 2016;36(12):6367–80.PubMedCrossRef
138.
Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen B, et al. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial–mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. OncoTargets Ther. 2015;8:2989.CrossRef
139.
Wang Q, Wang H, Jia Y, Ding H, Zhang L, Pan H. Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p–IGF–1R/PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2017;14(3):3545–51.PubMedPubMedCentralCrossRef
140.
Liang L, Li L, Zeng J, Gao Y, Chen Y-L, Wang Z-Q, et al. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep. 2012;28(3):999–1005.PubMed
141.
Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy. 2007;3(6):635–7.PubMedCrossRef
142.
Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B‐Raf/mitogen‐activated/extracellular signal‐regulated protein kinase pathway and the akt pathway. Cancer. 2005;104(4):879–90.PubMedCrossRef
143.
Liu S-C, Chen C, Chung C-H, Wang P-C, Wu N-L, Cheng J-K, et al. Inhibitory effects of butein on cancer metastasis and bioenergetic modulation. J Agric Food Chem. 2014;62(37):9109–17.PubMedCrossRef
144.
Buhrmann C, Shayan P, Goel A, Shakibaei M. Resveratrol regulates colorectal cancer cell invasion by modulation of focal adhesion molecules. Nutrients. 2017;9(10):1073.PubMedPubMedCentralCrossRef
145.
Wee LH, Morad NA, Aan GJ, Makpol S, Ngah WZW, Yusof YAM. Mechanism of chemoprevention against colon cancer cells using combined Gelam honey and ginger extract via mTOR and Wnt/β-catenin pathways. Asian Pac J Cancer Prev. 2015;16(15):6549–56.PubMedCrossRef
146.
Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-κ B in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene. 2003;22(31):4851–9.PubMedCrossRef
147.
An H, Yu X, Xiang C, Zhang Y, Xia J, Wang Y, Baicalein. U0126 suppress human breast cancer cell line MCF-7 through regulating MAPK signaling pathway. Int J Clin Exp Pathol. 2016;9(10):10266–73.
148.
Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, et al. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial–mesenchymal transition. BioFactors. 2017;43(2):152–69.PubMedCrossRef
Metadata
Title
Flavonoids target different molecules of autophagic and metastatic pathways in cancer cells
Authors
Aysooda Hosseinzadeh
Faezeh Poursoleiman
Akram Naghdipour Biregani
Ahmad Esmailzadeh
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-02960-4

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Research

Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies

Research

MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway

Research

Polyploid giant cancer cells, cytokines and cytomegalovirus in breast cancer progression

Review

Recent advances in non-small cell lung cancer targeted therapy; an update review

Research

HADHA promotes ovarian cancer outgrowth via up-regulating CDK1

Review

Diverse activity of miR-150 in Tumor development: shedding light on the potential mechanisms

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

Read more

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

Live event concluded

In this webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version
Image Credits